Address
2117 SW Highway 484
Ocala, FL 34473
United States of America (the)
Phone
352 448 7797
Website
Sector
Healthcare
Industry
Biotechnology
Employees
19
First IPO Date
November 02, 1995
| Name | Title | Pay | Year Born |
| Thomas K. Equels | Executive Vice Chairman, Chief Executive Officer & President | 681,316 | 1953 |
| Robert Dickey | Chief Financial Officer | 108,420 | 1956 |
| Peter W. Rodino | Chief Operating Officer, Executive Director of Governmental Relations, General Counsel & Secretary | 386,181 | 1951 |
| Ann Marie E. Coverly | Director of Administration & Human Resources and Deputy Investor Relations Coordinator | 0 | N/A |
| Christopher Nicodemus FACP | Member of Scientific Advisory Board & Consulting Science Officer | 0 | N/A |
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.